穴位注射喘可治联合舒利迭治疗慢性阻塞性肺疾病稳定期的临床观察

Clinical Observation on Acupoint Injection of Chuankezhi Injection Combined Seretide on COPD in Stable Phase

目的观察穴位注射喘可治联合舒利迭对慢性阻塞性肺疾病(COPD)稳定期GOLDⅢ~Ⅳ级患者的疗效。方法将90例病例按随机数字表法分为单纯舒利迭吸入组(A组),舒利迭吸入联合0.9%氯化钠注射液穴位注射组(B组)和舒利迭吸入联合喘可治穴位注射组(C组)各30例,3组常规予舒利迭(50/250μg)每日2次,每次1吸,吸入。疗程为6个月。B组予双侧足三里穴位注射0.9%氯化钠注射液,每穴2 m L,每周2次。疗程为6个月。C组予喘可治注射液双侧足三里穴穴位注射,每穴2 m L,每周2次。疗程为6个月。测定并比较各组治疗前后的慢阻肺患者自我评估测试(CAT)评分,中医证候评分,FEV1,FEV1/FVC,FEV1%,6min步行距离(6MWD)。结果治疗后3组CAT评分、中医证候评分均明显降低,其中C组降低最为显著(P<0.05),FEV1,FEV1/FVC,FEV1%,6MWD均显著升高,其中C组升高最为显著(P<0.05)。结论舒利迭联合喘可治穴位注射治疗肺肾气虚型GOLD分级Ⅲ~Ⅳ级稳定期COPD的疗效优于单用舒利迭。

Objective： To investigate the effect of acupoint injection of Chuankezhi Injection combined Seretide on stable COPD patients with GOLD Ⅲ~Ⅳ. Methods： 90 cases were randomly divided into three groups,Simple Seretide inhalation group（group A）,Seretide inhalation combined with acupoint injection of normal saline group（group B） and Seretide inhalation combined with Chuankezhi Injection group（group C）,30 cases in each group.Three groups of conventional medication： Seretide（50/250 μg） once 1 inhalation,twice per day,the treatment course for 6 months. Group B： normal saline,4 m L each time,bilateral Zusanli acupoint injection,twice a week,the treatment course for 6 months. Group C：Chuankezhi Injection,4 m L each time,bilateral Zusanli acupoint injection,twice a week,the treatment course for 6 months. Before and after treatment,the CAT score,TCM syndrome score,FEV1,FEV1/FVC,FEV1% and 6MWD were detected and compared within the groups and among the groups. Results： The CAT score and TCM symptom score were significantly reduced after treatment in all three groups. Group C was the most significant,and the difference was statistically significant（P 〈 0.05）. FEV1,FEV1/FVC,FEV1% and 6MWD were significantly increased in all three groups. Group C was the most significant,and the difference was statistically significant（P 〈 0.05）. Conclusions： The curative effect of Seretide combined with Chuankezhi injection in the treatment of lung and kidney Qi deficiency on stable COPD patients with GOLD IIIIV is better than that of single Seretide.